Michael Verneris
Concepts (666)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 95 | 2023 | 520 | 15.490 |
Why?
| Killer Cells, Natural | 52 | 2020 | 380 | 8.150 |
Why?
| Graft vs Host Disease | 52 | 2022 | 212 | 7.530 |
Why?
| Transplantation Conditioning | 42 | 2021 | 151 | 6.030 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 37 | 2023 | 256 | 5.720 |
Why?
| Cord Blood Stem Cell Transplantation | 33 | 2021 | 91 | 5.310 |
Why?
| Hematologic Neoplasms | 27 | 2021 | 137 | 3.400 |
Why?
| Leukemia, Myeloid, Acute | 28 | 2022 | 534 | 3.190 |
Why?
| Transplantation, Homologous | 44 | 2022 | 377 | 3.070 |
Why?
| Unrelated Donors | 21 | 2021 | 37 | 2.900 |
Why?
| Fetal Blood | 15 | 2017 | 270 | 2.870 |
Why?
| Leukemia | 20 | 2023 | 209 | 2.840 |
Why?
| Hematopoietic Stem Cells | 9 | 2020 | 343 | 2.540 |
Why?
| Myelodysplastic Syndromes | 16 | 2020 | 119 | 2.090 |
Why?
| Immunity, Innate | 7 | 2021 | 720 | 1.960 |
Why?
| Antibodies, Bispecific | 5 | 2021 | 32 | 1.950 |
Why?
| Cell Differentiation | 13 | 2022 | 1701 | 1.750 |
Why?
| Neoplasm, Residual | 7 | 2021 | 104 | 1.650 |
Why?
| Immunotherapy, Adoptive | 21 | 2023 | 184 | 1.500 |
Why?
| Bone Marrow Transplantation | 12 | 2017 | 239 | 1.490 |
Why?
| Haplotypes | 4 | 2021 | 448 | 1.480 |
Why?
| Recurrence | 31 | 2023 | 935 | 1.460 |
Why?
| Disease-Free Survival | 29 | 2021 | 620 | 1.440 |
Why?
| CD56 Antigen | 9 | 2020 | 34 | 1.420 |
Why?
| Humans | 211 | 2023 | 114699 | 1.360 |
Why?
| Child | 88 | 2023 | 18420 | 1.350 |
Why?
| Receptors, Antigen, T-Cell | 13 | 2023 | 615 | 1.340 |
Why?
| Young Adult | 67 | 2023 | 10471 | 1.300 |
Why?
| Child, Preschool | 61 | 2022 | 9118 | 1.290 |
Why?
| HLA Antigens | 9 | 2017 | 225 | 1.250 |
Why?
| Adolescent | 84 | 2022 | 17853 | 1.240 |
Why?
| Antineoplastic Agents | 12 | 2021 | 1879 | 1.240 |
Why?
| Interleukins | 4 | 2015 | 236 | 1.210 |
Why?
| Cytomegalovirus Infections | 7 | 2019 | 180 | 1.170 |
Why?
| Receptors, IgG | 8 | 2019 | 67 | 1.160 |
Why?
| Lymphoid Tissue | 3 | 2021 | 62 | 1.130 |
Why?
| T-Lymphocytes, Helper-Inducer | 2 | 2019 | 127 | 1.090 |
Why?
| Graft Survival | 9 | 2018 | 446 | 1.080 |
Why?
| Adult | 93 | 2023 | 30553 | 1.080 |
Why?
| Immunotherapy | 9 | 2021 | 474 | 1.070 |
Why?
| Cell- and Tissue-Based Therapy | 3 | 2021 | 56 | 1.070 |
Why?
| Infant | 47 | 2022 | 7964 | 1.050 |
Why?
| Lymphocytes | 6 | 2020 | 330 | 1.030 |
Why?
| Cytokines | 10 | 2018 | 1841 | 1.010 |
Why?
| Virus Activation | 4 | 2019 | 78 | 0.990 |
Why?
| Receptors, KIR | 9 | 2015 | 92 | 0.990 |
Why?
| Antigens, CD | 6 | 2019 | 442 | 0.990 |
Why?
| Male | 109 | 2021 | 55606 | 0.980 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 64 | 0.980 |
Why?
| Survival Analysis | 23 | 2020 | 1211 | 0.960 |
Why?
| Cryopreservation | 2 | 2017 | 92 | 0.960 |
Why?
| Female | 112 | 2021 | 59520 | 0.960 |
Why?
| Treatment Outcome | 44 | 2021 | 9088 | 0.950 |
Why?
| Histocompatibility Testing | 10 | 2018 | 116 | 0.950 |
Why?
| Whole-Body Irradiation | 8 | 2018 | 73 | 0.940 |
Why?
| Middle Aged | 71 | 2021 | 26738 | 0.920 |
Why?
| Tissue Donors | 9 | 2019 | 316 | 0.900 |
Why?
| Pluripotent Stem Cells | 2 | 2022 | 63 | 0.900 |
Why?
| Adoptive Transfer | 4 | 2017 | 195 | 0.880 |
Why?
| Histocompatibility | 6 | 2019 | 26 | 0.880 |
Why?
| Cytomegalovirus | 8 | 2019 | 144 | 0.850 |
Why?
| Stem Cell Transplantation | 3 | 2019 | 149 | 0.830 |
Why?
| Graft vs Leukemia Effect | 3 | 2013 | 12 | 0.820 |
Why?
| Peripheral Blood Stem Cell Transplantation | 3 | 2018 | 19 | 0.810 |
Why?
| Hemangioblasts | 1 | 2022 | 4 | 0.810 |
Why?
| Lymphocyte Depletion | 5 | 2019 | 116 | 0.810 |
Why?
| HLA-C Antigens | 3 | 2016 | 33 | 0.800 |
Why?
| Receptors, Immunologic | 6 | 2016 | 201 | 0.770 |
Why?
| Lymphoid Progenitor Cells | 2 | 2020 | 11 | 0.760 |
Why?
| Interferon-gamma | 9 | 2014 | 719 | 0.740 |
Why?
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 3 | 0.730 |
Why?
| CD48 Antigen | 1 | 2020 | 2 | 0.730 |
Why?
| Bone Marrow | 9 | 2017 | 243 | 0.730 |
Why?
| Receptors, Prolactin | 1 | 2020 | 8 | 0.700 |
Why?
| Leukemia, Myeloid | 2 | 2017 | 40 | 0.700 |
Why?
| Smad7 Protein | 1 | 2020 | 19 | 0.690 |
Why?
| Antigens, CD19 | 10 | 2023 | 91 | 0.690 |
Why?
| Lymphopoiesis | 1 | 2020 | 24 | 0.690 |
Why?
| Burkitt Lymphoma | 4 | 2023 | 52 | 0.680 |
Why?
| Monocytes | 3 | 2020 | 504 | 0.680 |
Why?
| Bone Neoplasms | 3 | 2010 | 194 | 0.680 |
Why?
| Prolactin | 1 | 2020 | 96 | 0.680 |
Why?
| Cell Proliferation | 12 | 2019 | 2187 | 0.660 |
Why?
| Transplantation Chimera | 2 | 2019 | 51 | 0.660 |
Why?
| Crohn Disease | 1 | 2022 | 196 | 0.660 |
Why?
| Transplantation, Autologous | 4 | 2019 | 176 | 0.660 |
Why?
| Interleukin-2 | 5 | 2019 | 413 | 0.650 |
Why?
| Cells, Cultured | 15 | 2022 | 3886 | 0.650 |
Why?
| Transforming Growth Factor beta1 | 1 | 2020 | 153 | 0.640 |
Why?
| Sarcoma, Ewing | 3 | 2010 | 64 | 0.640 |
Why?
| GATA3 Transcription Factor | 1 | 2019 | 24 | 0.640 |
Why?
| Interleukin-15 | 5 | 2019 | 74 | 0.640 |
Why?
| T-Lymphocytes | 11 | 2023 | 1737 | 0.640 |
Why?
| Aged | 46 | 2021 | 19074 | 0.630 |
Why?
| Retrospective Studies | 35 | 2023 | 12555 | 0.620 |
Why?
| Survival Rate | 18 | 2020 | 1644 | 0.620 |
Why?
| Inflammatory Bowel Diseases | 1 | 2022 | 284 | 0.620 |
Why?
| Allografts | 13 | 2021 | 122 | 0.610 |
Why?
| Adipokines | 1 | 2018 | 42 | 0.610 |
Why?
| Immune Reconstitution | 1 | 2018 | 6 | 0.610 |
Why?
| Piperazines | 3 | 2009 | 309 | 0.600 |
Why?
| Histocompatibility Antigens Class I | 4 | 2019 | 172 | 0.600 |
Why?
| Cell Lineage | 3 | 2020 | 309 | 0.600 |
Why?
| Delayed Graft Function | 1 | 2018 | 26 | 0.600 |
Why?
| Gene Expression Regulation | 4 | 2019 | 2320 | 0.580 |
Why?
| Pyrimidines | 3 | 2009 | 376 | 0.580 |
Why?
| T-Lymphocytes, Regulatory | 4 | 2015 | 339 | 0.560 |
Why?
| Acute Disease | 17 | 2019 | 911 | 0.560 |
Why?
| Blood Donors | 4 | 2016 | 89 | 0.560 |
Why?
| Antigens, CD34 | 4 | 2022 | 89 | 0.550 |
Why?
| Stromal Cells | 4 | 2011 | 97 | 0.550 |
Why?
| Siblings | 7 | 2019 | 221 | 0.540 |
Why?
| Myeloid Progenitor Cells | 2 | 2020 | 15 | 0.540 |
Why?
| Time Factors | 17 | 2019 | 6116 | 0.530 |
Why?
| Prognosis | 15 | 2021 | 3329 | 0.530 |
Why?
| Neoplasms | 9 | 2022 | 2097 | 0.530 |
Why?
| Cell Degranulation | 3 | 2013 | 39 | 0.530 |
Why?
| Bone Marrow Cells | 3 | 2020 | 267 | 0.530 |
Why?
| Lymphocyte Activation | 12 | 2016 | 1037 | 0.520 |
Why?
| Lymphoma, B-Cell | 4 | 2023 | 86 | 0.510 |
Why?
| Pulmonary Embolism | 2 | 2010 | 181 | 0.510 |
Why?
| Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2015 | 3 | 0.500 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2015 | 8 | 0.500 |
Why?
| Self Tolerance | 2 | 2013 | 28 | 0.500 |
Why?
| Mitochondria | 4 | 2021 | 747 | 0.490 |
Why?
| Up-Regulation | 3 | 2015 | 808 | 0.490 |
Why?
| Receptors, Calcitriol | 1 | 2014 | 53 | 0.460 |
Why?
| Calcitriol | 1 | 2014 | 53 | 0.460 |
Why?
| Mice | 21 | 2023 | 14871 | 0.450 |
Why?
| Recombinant Fusion Proteins | 5 | 2021 | 616 | 0.450 |
Why?
| Neoplasm Recurrence, Local | 6 | 2018 | 858 | 0.450 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2009 | 95 | 0.450 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2016 | 959 | 0.450 |
Why?
| Donor Selection | 4 | 2018 | 66 | 0.430 |
Why?
| Mycophenolic Acid | 3 | 2016 | 77 | 0.430 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2013 | 15 | 0.430 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2013 | 24 | 0.430 |
Why?
| Vitamins | 1 | 2014 | 151 | 0.430 |
Why?
| Single-Chain Antibodies | 1 | 2013 | 14 | 0.430 |
Why?
| CD8-Positive T-Lymphocytes | 6 | 2018 | 687 | 0.420 |
Why?
| Immunophenotyping | 8 | 2019 | 274 | 0.420 |
Why?
| NK Cell Lectin-Like Receptor Subfamily C | 4 | 2015 | 8 | 0.420 |
Why?
| Cytotoxicity, Immunologic | 10 | 2016 | 195 | 0.410 |
Why?
| Metabolic Syndrome | 1 | 2016 | 321 | 0.410 |
Why?
| Chromosome Aberrations | 1 | 2013 | 135 | 0.410 |
Why?
| Remission Induction | 9 | 2018 | 233 | 0.390 |
Why?
| Immunosuppressive Agents | 4 | 2015 | 646 | 0.390 |
Why?
| Fibroblast Growth Factor 7 | 1 | 2011 | 16 | 0.390 |
Why?
| Lymphocyte Count | 4 | 2017 | 133 | 0.390 |
Why?
| Carcinoma | 1 | 2013 | 198 | 0.380 |
Why?
| Cell Communication | 1 | 2013 | 280 | 0.370 |
Why?
| Animals | 26 | 2023 | 31708 | 0.360 |
Why?
| Lymphocyte Subsets | 3 | 2021 | 79 | 0.360 |
Why?
| Salvage Therapy | 1 | 2011 | 127 | 0.360 |
Why?
| Graft vs Tumor Effect | 3 | 2017 | 8 | 0.350 |
Why?
| Sialic Acid Binding Ig-like Lectin 3 | 3 | 2016 | 8 | 0.350 |
Why?
| Body Mass Index | 1 | 2018 | 1959 | 0.350 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 1355 | 0.350 |
Why?
| Incidence | 8 | 2019 | 2313 | 0.350 |
Why?
| Heparin | 1 | 2011 | 224 | 0.350 |
Why?
| K562 Cells | 6 | 2014 | 73 | 0.340 |
Why?
| Infant, Newborn | 9 | 2019 | 5047 | 0.340 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2021 | 152 | 0.330 |
Why?
| Medical Oncology | 1 | 2011 | 229 | 0.330 |
Why?
| Cyclosporine | 3 | 2016 | 161 | 0.330 |
Why?
| Myeloablative Agonists | 5 | 2016 | 21 | 0.320 |
Why?
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.320 |
Why?
| Influenza Vaccines | 2 | 2016 | 497 | 0.310 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 43 | 0.310 |
Why?
| Philadelphia Chromosome | 1 | 2008 | 15 | 0.310 |
Why?
| Hematopoiesis | 3 | 2020 | 171 | 0.310 |
Why?
| Single-Cell Analysis | 2 | 2020 | 188 | 0.310 |
Why?
| Follow-Up Studies | 9 | 2020 | 4411 | 0.300 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 56 | 0.300 |
Why?
| Antibodies | 5 | 2018 | 371 | 0.300 |
Why?
| Lymphocyte Transfusion | 3 | 2016 | 19 | 0.300 |
Why?
| Gene Expression Regulation, Leukemic | 2 | 2019 | 49 | 0.300 |
Why?
| Risk Factors | 18 | 2021 | 8632 | 0.300 |
Why?
| Epidermal Growth Factor | 3 | 2017 | 161 | 0.300 |
Why?
| Natural Killer T-Cells | 1 | 2008 | 63 | 0.300 |
Why?
| Kaplan-Meier Estimate | 6 | 2021 | 811 | 0.290 |
Why?
| Chronic Disease | 6 | 2023 | 1578 | 0.290 |
Why?
| Cell Count | 3 | 2014 | 303 | 0.290 |
Why?
| Coculture Techniques | 5 | 2020 | 201 | 0.290 |
Why?
| GPI-Linked Proteins | 4 | 2019 | 54 | 0.280 |
Why?
| Polymorphism, Genetic | 3 | 2016 | 610 | 0.280 |
Why?
| Cell Line, Tumor | 9 | 2016 | 2710 | 0.280 |
Why?
| Alleles | 4 | 2017 | 789 | 0.280 |
Why?
| Immunologic Memory | 4 | 2016 | 313 | 0.270 |
Why?
| HLA-DP beta-Chains | 2 | 2017 | 76 | 0.270 |
Why?
| Hyperglycemia | 2 | 2020 | 292 | 0.260 |
Why?
| Peritoneal Dialysis | 1 | 2007 | 84 | 0.260 |
Why?
| Matrix Metalloproteinases | 1 | 2007 | 89 | 0.260 |
Why?
| Neuroblastoma | 1 | 2007 | 133 | 0.260 |
Why?
| Cell Separation | 3 | 2020 | 291 | 0.260 |
Why?
| Apoptosis | 7 | 2011 | 2363 | 0.260 |
Why?
| CD57 Antigens | 3 | 2015 | 15 | 0.250 |
Why?
| Heart Diseases | 1 | 2009 | 331 | 0.250 |
Why?
| Neoplasms, Experimental | 2 | 2005 | 151 | 0.250 |
Why?
| Blood Platelets | 3 | 2021 | 351 | 0.240 |
Why?
| Imatinib Mesylate | 3 | 2009 | 63 | 0.240 |
Why?
| Radiotherapy, Intensity-Modulated | 3 | 2013 | 124 | 0.240 |
Why?
| Hepatitis A Virus Cellular Receptor 2 | 2 | 2023 | 26 | 0.240 |
Why?
| Chimerism | 2 | 2021 | 28 | 0.240 |
Why?
| Membrane Proteins | 8 | 2015 | 1019 | 0.230 |
Why?
| Diphtheria Toxin | 2 | 2015 | 51 | 0.230 |
Why?
| Cohort Studies | 12 | 2021 | 4895 | 0.230 |
Why?
| Neoplasm Proteins | 3 | 2017 | 385 | 0.230 |
Why?
| Benzamides | 3 | 2009 | 169 | 0.230 |
Why?
| Risk | 3 | 2018 | 812 | 0.230 |
Why?
| Drug Resistance, Neoplasm | 3 | 2018 | 636 | 0.230 |
Why?
| Follistatin | 3 | 2019 | 12 | 0.220 |
Why?
| Major Histocompatibility Complex | 2 | 2018 | 217 | 0.220 |
Why?
| Neutrophils | 4 | 2017 | 1176 | 0.220 |
Why?
| Mutation | 4 | 2019 | 3346 | 0.220 |
Why?
| Endoglin | 3 | 2019 | 20 | 0.210 |
Why?
| Protein Kinase Inhibitors | 1 | 2009 | 785 | 0.210 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 28 | 0.210 |
Why?
| Receptors, Natural Killer Cell | 4 | 2014 | 16 | 0.210 |
Why?
| Receptor, ErbB-2 | 1 | 2005 | 300 | 0.210 |
Why?
| Practice Patterns, Physicians' | 1 | 2011 | 1177 | 0.210 |
Why?
| Flow Cytometry | 5 | 2020 | 1083 | 0.210 |
Why?
| fms-Like Tyrosine Kinase 3 | 2 | 2020 | 43 | 0.200 |
Why?
| Maximum Tolerated Dose | 3 | 2017 | 183 | 0.200 |
Why?
| Signal Transduction | 7 | 2020 | 4515 | 0.200 |
Why?
| Severity of Illness Index | 4 | 2021 | 2540 | 0.200 |
Why?
| Proteins | 4 | 2018 | 908 | 0.190 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2021 | 3 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2018 | 1880 | 0.190 |
Why?
| Genetic Variation | 2 | 2017 | 870 | 0.190 |
Why?
| Multivariate Analysis | 5 | 2014 | 1430 | 0.190 |
Why?
| Thrombopoietin | 1 | 2021 | 4 | 0.190 |
Why?
| CD3 Complex | 2 | 2001 | 92 | 0.190 |
Why?
| fas Receptor | 2 | 2003 | 91 | 0.190 |
Why?
| CD52 Antigen | 1 | 2020 | 3 | 0.180 |
Why?
| Carcinoma, Papillary | 1 | 2001 | 73 | 0.180 |
Why?
| Lymphoma | 2 | 2003 | 177 | 0.180 |
Why?
| Receptors, Fc | 1 | 2021 | 45 | 0.180 |
Why?
| Heterografts | 1 | 2021 | 117 | 0.180 |
Why?
| Cell Survival | 2 | 2014 | 1021 | 0.180 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2022 | 198 | 0.180 |
Why?
| Osteosarcoma | 1 | 2001 | 67 | 0.180 |
Why?
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 11 | 0.180 |
Why?
| Cell Culture Techniques | 4 | 2011 | 343 | 0.180 |
Why?
| Gene Knockout Techniques | 1 | 2020 | 98 | 0.180 |
Why?
| Graft Rejection | 4 | 2021 | 513 | 0.180 |
Why?
| Primary Cell Culture | 1 | 2020 | 149 | 0.170 |
Why?
| Neoplasms, Second Primary | 1 | 2001 | 92 | 0.170 |
Why?
| Arabidopsis Proteins | 1 | 2000 | 65 | 0.170 |
Why?
| Immune System | 1 | 2021 | 172 | 0.170 |
Why?
| Pneumococcal Vaccines | 1 | 2021 | 131 | 0.170 |
Why?
| Cell Self Renewal | 1 | 2019 | 49 | 0.170 |
Why?
| Biomarkers | 6 | 2015 | 3408 | 0.170 |
Why?
| Species Specificity | 1 | 2020 | 542 | 0.160 |
Why?
| Blast Crisis | 2 | 2017 | 20 | 0.160 |
Why?
| Mice, SCID | 5 | 2021 | 314 | 0.160 |
Why?
| Interleukin-2 Receptor beta Subunit | 1 | 2019 | 19 | 0.160 |
Why?
| Combined Modality Therapy | 5 | 2021 | 1121 | 0.160 |
Why?
| Linkage Disequilibrium | 2 | 2016 | 245 | 0.160 |
Why?
| Prospective Studies | 6 | 2023 | 6220 | 0.160 |
Why?
| Pilot Projects | 2 | 2021 | 1373 | 0.160 |
Why?
| Radiotherapy Dosage | 3 | 2016 | 244 | 0.160 |
Why?
| Leukocytes, Mononuclear | 1 | 2021 | 493 | 0.160 |
Why?
| Lipopolysaccharide Receptors | 1 | 2019 | 81 | 0.150 |
Why?
| Busulfan | 1 | 2018 | 14 | 0.150 |
Why?
| Tomography, X-Ray Computed | 3 | 2017 | 2286 | 0.150 |
Why?
| Thyroid Neoplasms | 1 | 2001 | 264 | 0.150 |
Why?
| HLA-DRB1 Chains | 1 | 2018 | 98 | 0.150 |
Why?
| Pediatrics | 2 | 2019 | 981 | 0.150 |
Why?
| Telomere Homeostasis | 1 | 2017 | 24 | 0.150 |
Why?
| Cell Line | 3 | 2011 | 2637 | 0.140 |
Why?
| Homeostasis | 1 | 2021 | 573 | 0.140 |
Why?
| Ambulatory Care | 1 | 2021 | 478 | 0.140 |
Why?
| Proportional Hazards Models | 3 | 2015 | 1075 | 0.140 |
Why?
| Central Nervous System Neoplasms | 1 | 2019 | 126 | 0.140 |
Why?
| Epithelial Cell Adhesion Molecule | 2 | 2016 | 10 | 0.140 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2021 | 698 | 0.140 |
Why?
| Antibodies, Neoplasm | 1 | 2017 | 30 | 0.140 |
Why?
| Vidarabine | 4 | 2022 | 26 | 0.140 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2017 | 39 | 0.140 |
Why?
| Vascularized Composite Allotransplantation | 1 | 2017 | 22 | 0.140 |
Why?
| Age Factors | 5 | 2021 | 2894 | 0.140 |
Why?
| Dideoxynucleosides | 1 | 2017 | 20 | 0.140 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 10 | 0.140 |
Why?
| Receptors, OX40 | 1 | 2016 | 15 | 0.140 |
Why?
| Roseolovirus Infections | 1 | 2016 | 7 | 0.140 |
Why?
| Lymphoma, Non-Hodgkin | 2 | 2015 | 71 | 0.140 |
Why?
| 5-Methylcytosine | 1 | 2016 | 16 | 0.140 |
Why?
| Antibodies, Monoclonal | 3 | 2017 | 1262 | 0.140 |
Why?
| Herpesvirus 6, Human | 1 | 2016 | 13 | 0.140 |
Why?
| Secondary Prevention | 3 | 2014 | 222 | 0.140 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2016 | 17 | 0.130 |
Why?
| Transplantation | 1 | 2016 | 23 | 0.130 |
Why?
| Whole Body Imaging | 1 | 2016 | 19 | 0.130 |
Why?
| Radiotherapy, Image-Guided | 1 | 2016 | 30 | 0.130 |
Why?
| Leuprolide | 1 | 2016 | 19 | 0.130 |
Why?
| Mortality | 1 | 2018 | 287 | 0.130 |
Why?
| Neoplastic Stem Cells | 1 | 2019 | 329 | 0.130 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2017 | 170 | 0.130 |
Why?
| Immune System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
| Sociobiology | 1 | 2015 | 2 | 0.130 |
Why?
| T-Lymphocyte Subsets | 1 | 2018 | 383 | 0.130 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 56 | 0.130 |
Why?
| Interleukin-23 Subunit p19 | 1 | 2015 | 5 | 0.130 |
Why?
| Disease Models, Animal | 3 | 2021 | 3535 | 0.130 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2016 | 139 | 0.130 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 16 | 0.120 |
Why?
| Positron-Emission Tomography | 1 | 2017 | 259 | 0.120 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 921 | 0.120 |
Why?
| Receptors, KIR2DL1 | 1 | 2015 | 18 | 0.120 |
Why?
| Radiotherapy Planning, Computer-Assisted | 2 | 2013 | 117 | 0.120 |
Why?
| DNA Methylation | 2 | 2016 | 495 | 0.120 |
Why?
| Sirolimus | 1 | 2016 | 181 | 0.120 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 66 | 0.120 |
Why?
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2015 | 11 | 0.120 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2020 | 801 | 0.120 |
Why?
| Cyclophosphamide | 4 | 2014 | 217 | 0.120 |
Why?
| Radiotherapy, Computer-Assisted | 1 | 2014 | 12 | 0.120 |
Why?
| Neutropenia | 1 | 2015 | 125 | 0.120 |
Why?
| Models, Biological | 2 | 2020 | 1621 | 0.120 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2016 | 188 | 0.120 |
Why?
| Ovary | 1 | 2016 | 191 | 0.120 |
Why?
| Radiation Dosage | 1 | 2015 | 133 | 0.120 |
Why?
| DNA Repair | 1 | 2016 | 184 | 0.120 |
Why?
| DNA, Viral | 1 | 2016 | 350 | 0.120 |
Why?
| Machine Learning | 1 | 2018 | 316 | 0.120 |
Why?
| Radiotherapy, Conformal | 1 | 2014 | 68 | 0.120 |
Why?
| Hypoglycemia | 1 | 2019 | 387 | 0.120 |
Why?
| Interleukin-8 | 1 | 2015 | 237 | 0.110 |
Why?
| RNA, Messenger | 4 | 2013 | 2553 | 0.110 |
Why?
| Mice, Inbred NOD | 4 | 2021 | 555 | 0.110 |
Why?
| Dendritic Cells | 1 | 2017 | 435 | 0.110 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 1995 | 152 | 0.110 |
Why?
| Arabinonucleosides | 1 | 2013 | 8 | 0.110 |
Why?
| Adenine Nucleotides | 1 | 2013 | 18 | 0.110 |
Why?
| Phantoms, Imaging | 1 | 2014 | 123 | 0.110 |
Why?
| Genetic Predisposition to Disease | 3 | 2016 | 2086 | 0.110 |
Why?
| Toll-Like Receptor 5 | 1 | 2013 | 14 | 0.110 |
Why?
| Receptors, Notch | 1 | 2014 | 84 | 0.110 |
Why?
| CTLA-4 Antigen | 1 | 2014 | 76 | 0.110 |
Why?
| Embryonic Stem Cells | 2 | 2017 | 106 | 0.110 |
Why?
| Tomography, Spiral Computed | 2 | 2014 | 23 | 0.110 |
Why?
| Antiviral Agents | 1 | 2019 | 645 | 0.110 |
Why?
| Binding Sites | 1 | 2016 | 1168 | 0.110 |
Why?
| Clinical Protocols | 1 | 2014 | 233 | 0.110 |
Why?
| Recovery of Function | 1 | 2017 | 574 | 0.110 |
Why?
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 11 | 0.110 |
Why?
| ADAM Proteins | 1 | 2013 | 58 | 0.110 |
Why?
| Pericardial Effusion | 1 | 2013 | 21 | 0.110 |
Why?
| Receptors, Cytokine | 1 | 2013 | 33 | 0.110 |
Why?
| Interleukin-1beta | 1 | 2015 | 370 | 0.100 |
Why?
| Body Size | 1 | 2013 | 92 | 0.100 |
Why?
| Living Donors | 1 | 2015 | 270 | 0.100 |
Why?
| Survivors | 1 | 2016 | 411 | 0.100 |
Why?
| Gene Expression Profiling | 4 | 2020 | 1518 | 0.100 |
Why?
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 34 | 0.100 |
Why?
| Health Status Indicators | 1 | 2013 | 156 | 0.100 |
Why?
| Promoter Regions, Genetic | 1 | 2016 | 1131 | 0.100 |
Why?
| Cell Adhesion Molecules | 1 | 2013 | 168 | 0.100 |
Why?
| CD4 Lymphocyte Count | 1 | 2012 | 257 | 0.100 |
Why?
| Galectins | 1 | 2012 | 22 | 0.100 |
Why?
| Apolipoprotein C-III | 2 | 2009 | 13 | 0.100 |
Why?
| Antigens, Viral | 1 | 2012 | 176 | 0.100 |
Why?
| Antibody Formation | 1 | 2013 | 266 | 0.100 |
Why?
| Antigens, Neoplasm | 1 | 2013 | 222 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2017 | 480 | 0.100 |
Why?
| Ligands | 3 | 2021 | 562 | 0.090 |
Why?
| Taxoids | 1 | 2011 | 93 | 0.090 |
Why?
| Blood Glucose | 1 | 2020 | 1828 | 0.090 |
Why?
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2011 | 1 | 0.090 |
Why?
| Oncogene Proteins, Fusion | 1 | 2013 | 179 | 0.090 |
Why?
| Antigens, CD20 | 1 | 2011 | 27 | 0.090 |
Why?
| Proteoglycans | 1 | 2011 | 107 | 0.090 |
Why?
| Leukemia, Experimental | 2 | 2009 | 27 | 0.090 |
Why?
| Colonic Neoplasms | 1 | 2013 | 215 | 0.090 |
Why?
| Influenza, Human | 1 | 2016 | 546 | 0.090 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 88 | 0.090 |
Why?
| Observer Variation | 1 | 2011 | 296 | 0.090 |
Why?
| Fas Ligand Protein | 2 | 2001 | 57 | 0.090 |
Why?
| Bone and Bones | 1 | 2013 | 279 | 0.090 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 63 | 0.090 |
Why?
| HL-60 Cells | 3 | 2016 | 28 | 0.090 |
Why?
| MicroRNAs | 1 | 2016 | 600 | 0.090 |
Why?
| Genotype | 1 | 2015 | 1760 | 0.090 |
Why?
| Umbilical Cord | 1 | 2010 | 80 | 0.090 |
Why?
| Serologic Tests | 1 | 2009 | 49 | 0.080 |
Why?
| Registries | 2 | 2015 | 1768 | 0.080 |
Why?
| Databases, Factual | 1 | 2014 | 1125 | 0.080 |
Why?
| Risk Assessment | 4 | 2021 | 2968 | 0.080 |
Why?
| Longitudinal Studies | 2 | 2015 | 2387 | 0.080 |
Why?
| Hydrocortisone | 1 | 2010 | 267 | 0.080 |
Why?
| Graft vs Host Reaction | 1 | 2008 | 1 | 0.080 |
Why?
| Head and Neck Neoplasms | 1 | 2013 | 427 | 0.080 |
Why?
| Glycosides | 1 | 2009 | 33 | 0.080 |
Why?
| Thoracic Vertebrae | 1 | 2009 | 68 | 0.080 |
Why?
| Leukemic Infiltration | 1 | 2008 | 5 | 0.080 |
Why?
| Membrane Glycoproteins | 2 | 2001 | 430 | 0.080 |
Why?
| Mice, Transgenic | 1 | 2013 | 1950 | 0.070 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2005 | 4 | 0.070 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 663 | 0.070 |
Why?
| Monomeric GTP-Binding Proteins | 1 | 2007 | 5 | 0.070 |
Why?
| Case-Control Studies | 4 | 2020 | 3003 | 0.070 |
Why?
| Double-Blind Method | 1 | 2011 | 1660 | 0.070 |
Why?
| Active Transport, Cell Nucleus | 1 | 2007 | 110 | 0.070 |
Why?
| NFATC Transcription Factors | 1 | 2007 | 78 | 0.070 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2006 | 16 | 0.070 |
Why?
| Bariatric Surgery | 1 | 2009 | 161 | 0.070 |
Why?
| Antigens, Differentiation | 1 | 2006 | 79 | 0.070 |
Why?
| Central Nervous System | 1 | 2008 | 235 | 0.070 |
Why?
| Liver Diseases | 1 | 2009 | 255 | 0.070 |
Why?
| Drug Monitoring | 1 | 2007 | 184 | 0.070 |
Why?
| Fibroma, Desmoplastic | 1 | 2006 | 2 | 0.070 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2006 | 11 | 0.070 |
Why?
| Aged, 80 and over | 4 | 2020 | 6347 | 0.060 |
Why?
| Regression Analysis | 1 | 2008 | 945 | 0.060 |
Why?
| Biomarkers, Tumor | 3 | 2019 | 1040 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2020 | 531 | 0.060 |
Why?
| Immunohistochemistry | 2 | 2011 | 1629 | 0.060 |
Why?
| Inflammation | 1 | 2016 | 2480 | 0.060 |
Why?
| Meningitis, Viral | 1 | 2005 | 21 | 0.060 |
Why?
| Metformin | 1 | 2009 | 276 | 0.060 |
Why?
| Calcium Signaling | 1 | 2007 | 217 | 0.060 |
Why?
| Anemia | 1 | 2006 | 143 | 0.060 |
Why?
| Immunity, Cellular | 1 | 2007 | 248 | 0.060 |
Why?
| RNA, Small Interfering | 2 | 2005 | 535 | 0.060 |
Why?
| Trastuzumab | 1 | 2005 | 89 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2019 | 498 | 0.060 |
Why?
| Mice, Knockout | 2 | 2021 | 2570 | 0.060 |
Why?
| Jurkat Cells | 2 | 2017 | 128 | 0.060 |
Why?
| Hemoglobins | 1 | 2006 | 315 | 0.060 |
Why?
| Cell Nucleus | 1 | 2007 | 554 | 0.060 |
Why?
| Phenotype | 3 | 2021 | 2797 | 0.060 |
Why?
| Feasibility Studies | 2 | 2019 | 740 | 0.060 |
Why?
| RNA Interference | 1 | 2005 | 433 | 0.060 |
Why?
| Postoperative Complications | 2 | 2015 | 2128 | 0.060 |
Why?
| Pregnancy | 3 | 2010 | 5520 | 0.060 |
Why?
| Plasma | 1 | 2005 | 211 | 0.060 |
Why?
| Immunocompromised Host | 1 | 2005 | 195 | 0.050 |
Why?
| Physicians | 1 | 2011 | 772 | 0.050 |
Why?
| Predictive Value of Tests | 2 | 2018 | 1796 | 0.050 |
Why?
| Liver | 1 | 2011 | 1637 | 0.050 |
Why?
| Erythroid Precursor Cells | 1 | 2003 | 4 | 0.050 |
Why?
| Sepsis | 1 | 2009 | 509 | 0.050 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2023 | 43 | 0.050 |
Why?
| beta-Thalassemia | 1 | 2003 | 23 | 0.050 |
Why?
| Enterovirus Infections | 1 | 2005 | 160 | 0.050 |
Why?
| Oxidants | 1 | 2003 | 112 | 0.050 |
Why?
| Killer Cells, Lymphokine-Activated | 1 | 2002 | 9 | 0.050 |
Why?
| United States | 3 | 2023 | 12186 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2013 | 1862 | 0.050 |
Why?
| In Vitro Techniques | 1 | 2003 | 1016 | 0.050 |
Why?
| Creatine Kinase | 1 | 2001 | 75 | 0.050 |
Why?
| Norpregnenes | 1 | 2001 | 3 | 0.050 |
Why?
| Werner Syndrome | 1 | 2001 | 5 | 0.050 |
Why?
| Dactinomycin | 1 | 2001 | 25 | 0.050 |
Why?
| Femoral Neoplasms | 1 | 2001 | 7 | 0.050 |
Why?
| HIV Infections | 1 | 1995 | 2469 | 0.050 |
Why?
| Luminescent Measurements | 1 | 2002 | 74 | 0.050 |
Why?
| Mice, Inbred BALB C | 2 | 2001 | 1144 | 0.050 |
Why?
| Thyroidectomy | 1 | 2001 | 53 | 0.050 |
Why?
| Perforin | 1 | 2001 | 18 | 0.050 |
Why?
| Vincristine | 1 | 2001 | 98 | 0.050 |
Why?
| Pore Forming Cytotoxic Proteins | 1 | 2001 | 15 | 0.050 |
Why?
| Thoracotomy | 1 | 2001 | 75 | 0.050 |
Why?
| Probability | 2 | 2013 | 289 | 0.050 |
Why?
| Immunization, Secondary | 1 | 2021 | 82 | 0.040 |
Why?
| Cycloheximide | 1 | 2000 | 54 | 0.040 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 154 | 0.040 |
Why?
| Chemokines, CXC | 1 | 2020 | 60 | 0.040 |
Why?
| Fatal Outcome | 2 | 2005 | 284 | 0.040 |
Why?
| Hospital Costs | 1 | 2021 | 104 | 0.040 |
Why?
| Lymphatic Metastasis | 1 | 2001 | 275 | 0.040 |
Why?
| Pneumonia, Viral | 1 | 2005 | 338 | 0.040 |
Why?
| Fatty Acid Desaturases | 1 | 2000 | 29 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2023 | 430 | 0.040 |
Why?
| Random Allocation | 1 | 2021 | 335 | 0.040 |
Why?
| Chemotherapy, Adjuvant | 1 | 2001 | 332 | 0.040 |
Why?
| Methotrexate | 1 | 2001 | 226 | 0.040 |
Why?
| Creatinine | 1 | 2001 | 425 | 0.040 |
Why?
| Doxorubicin | 1 | 2001 | 285 | 0.040 |
Why?
| Hodgkin Disease | 1 | 2001 | 121 | 0.040 |
Why?
| Placenta Growth Factor | 1 | 2019 | 22 | 0.040 |
Why?
| Microtubule-Associated Proteins | 1 | 2001 | 174 | 0.040 |
Why?
| Base Sequence | 1 | 2003 | 2114 | 0.040 |
Why?
| Cisplatin | 1 | 2001 | 262 | 0.040 |
Why?
| Eye Proteins | 1 | 2020 | 70 | 0.040 |
Why?
| Neuropeptides | 1 | 2020 | 65 | 0.040 |
Why?
| Perioperative Period | 1 | 2019 | 49 | 0.040 |
Why?
| Cost of Illness | 1 | 2021 | 254 | 0.040 |
Why?
| Bleomycin | 1 | 2001 | 228 | 0.040 |
Why?
| Aging | 1 | 2009 | 1618 | 0.040 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2000 | 171 | 0.040 |
Why?
| Gene Silencing | 1 | 2020 | 171 | 0.040 |
Why?
| Cell Compartmentation | 1 | 2019 | 51 | 0.040 |
Why?
| Microfilament Proteins | 1 | 2020 | 126 | 0.040 |
Why?
| Homozygote | 1 | 2019 | 187 | 0.040 |
Why?
| Loss of Heterozygosity | 1 | 2018 | 40 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2021 | 544 | 0.040 |
Why?
| Patient Safety | 1 | 2021 | 277 | 0.040 |
Why?
| Transforming Growth Factor beta | 1 | 2020 | 448 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 388 | 0.040 |
Why?
| Protein Phosphatase 2C | 1 | 2017 | 14 | 0.040 |
Why?
| Janus Kinase 2 | 1 | 2017 | 31 | 0.030 |
Why?
| Daunorubicin | 1 | 2016 | 24 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2018 | 371 | 0.030 |
Why?
| Rhodamines | 1 | 2016 | 17 | 0.030 |
Why?
| Genes, p53 | 1 | 2017 | 61 | 0.030 |
Why?
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 8 | 0.030 |
Why?
| Oxidative Stress | 1 | 2003 | 1076 | 0.030 |
Why?
| Radiography, Dual-Energy Scanned Projection | 1 | 2016 | 3 | 0.030 |
Why?
| Premedication | 1 | 2016 | 36 | 0.030 |
Why?
| Ovarian Function Tests | 1 | 2016 | 1 | 0.030 |
Why?
| Obesity | 1 | 2009 | 2508 | 0.030 |
Why?
| Orthomyxoviridae | 1 | 2016 | 35 | 0.030 |
Why?
| Transplants | 1 | 2016 | 36 | 0.030 |
Why?
| Lung | 1 | 2009 | 3561 | 0.030 |
Why?
| ROC Curve | 1 | 2018 | 442 | 0.030 |
Why?
| CD4 Antigens | 1 | 2016 | 123 | 0.030 |
Why?
| Validation Studies as Topic | 1 | 2016 | 23 | 0.030 |
Why?
| Calcineurin Inhibitors | 1 | 2016 | 58 | 0.030 |
Why?
| Receptors, Virus | 1 | 2016 | 75 | 0.030 |
Why?
| Growth Substances | 1 | 2016 | 138 | 0.030 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2016 | 127 | 0.030 |
Why?
| Myeloproliferative Disorders | 1 | 2016 | 26 | 0.030 |
Why?
| HLA-B Antigens | 1 | 2016 | 56 | 0.030 |
Why?
| Macrophages | 1 | 2023 | 1263 | 0.030 |
Why?
| HT29 Cells | 1 | 2016 | 35 | 0.030 |
Why?
| ras Proteins | 1 | 2017 | 138 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2016 | 109 | 0.030 |
Why?
| Th1 Cells | 1 | 2016 | 123 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2016 | 242 | 0.030 |
Why?
| Outpatients | 1 | 2019 | 326 | 0.030 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2016 | 104 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 372 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 157 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 134 | 0.030 |
Why?
| Nuclear Proteins | 1 | 2020 | 591 | 0.030 |
Why?
| Biological Transport | 1 | 2016 | 374 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2015 | 1842 | 0.030 |
Why?
| Angiopoietin-2 | 1 | 2015 | 11 | 0.030 |
Why?
| Follicle Stimulating Hormone | 1 | 2016 | 216 | 0.030 |
Why?
| Cadaver | 1 | 2016 | 299 | 0.030 |
Why?
| Protein Transport | 1 | 2016 | 395 | 0.030 |
Why?
| History, 21st Century | 1 | 2016 | 159 | 0.030 |
Why?
| Immunotoxins | 1 | 2015 | 33 | 0.030 |
Why?
| Precursor Cells, B-Lymphoid | 1 | 2015 | 34 | 0.030 |
Why?
| Blotting, Western | 2 | 2011 | 1147 | 0.030 |
Why?
| Jaw | 1 | 2014 | 16 | 0.030 |
Why?
| International Cooperation | 1 | 2015 | 171 | 0.030 |
Why?
| History, 20th Century | 1 | 2016 | 264 | 0.030 |
Why?
| Reproducibility of Results | 2 | 2016 | 2765 | 0.030 |
Why?
| Diagnostic Errors | 1 | 1995 | 149 | 0.030 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 19 | 0.030 |
Why?
| Models, Molecular | 1 | 2019 | 1369 | 0.030 |
Why?
| Computer Simulation | 1 | 2018 | 873 | 0.030 |
Why?
| Hydroxamic Acids | 1 | 2014 | 80 | 0.030 |
Why?
| Lung Neoplasms | 2 | 2009 | 2177 | 0.030 |
Why?
| Bones of Upper Extremity | 1 | 2013 | 3 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2014 | 181 | 0.030 |
Why?
| Etoposide | 1 | 2013 | 148 | 0.030 |
Why?
| Spiro Compounds | 1 | 2013 | 9 | 0.030 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2013 | 81 | 0.030 |
Why?
| Autoimmunity | 1 | 2019 | 813 | 0.030 |
Why?
| ADAM17 Protein | 1 | 2013 | 30 | 0.030 |
Why?
| Pericardiocentesis | 1 | 2013 | 9 | 0.030 |
Why?
| Azacitidine | 1 | 2014 | 129 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2014 | 206 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 355 | 0.030 |
Why?
| Myeloid Cells | 1 | 2014 | 126 | 0.030 |
Why?
| Academic Medical Centers | 1 | 2015 | 411 | 0.030 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 15 | 0.030 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 351 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2016 | 521 | 0.030 |
Why?
| Global Health | 1 | 2014 | 287 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 923 | 0.020 |
Why?
| Femur | 1 | 2013 | 191 | 0.020 |
Why?
| Kinetics | 1 | 2015 | 1551 | 0.020 |
Why?
| Receptors, KIR2DL2 | 1 | 2011 | 6 | 0.020 |
Why?
| Receptors, KIR2DL3 | 1 | 2011 | 8 | 0.020 |
Why?
| Spine | 1 | 2013 | 136 | 0.020 |
Why?
| Terminology as Topic | 1 | 2013 | 187 | 0.020 |
Why?
| Remission, Spontaneous | 1 | 2011 | 37 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2016 | 1693 | 0.020 |
Why?
| Immune Tolerance | 1 | 2014 | 323 | 0.020 |
Why?
| Piperidines | 1 | 2013 | 160 | 0.020 |
Why?
| Immunocompetence | 1 | 2011 | 40 | 0.020 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2011 | 5 | 0.020 |
Why?
| Stem Cells | 1 | 2016 | 546 | 0.020 |
Why?
| ABO Blood-Group System | 1 | 2011 | 32 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1141 | 0.020 |
Why?
| Colorado | 1 | 2021 | 4100 | 0.020 |
Why?
| Drug Synergism | 1 | 2011 | 316 | 0.020 |
Why?
| Algorithms | 1 | 2018 | 1470 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 313 | 0.020 |
Why?
| Antilymphocyte Serum | 1 | 2010 | 60 | 0.020 |
Why?
| Seasons | 1 | 2013 | 442 | 0.020 |
Why?
| Epitopes | 1 | 2012 | 435 | 0.020 |
Why?
| Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2010 | 2 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2016 | 1177 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2015 | 766 | 0.020 |
Why?
| HEK293 Cells | 1 | 2012 | 591 | 0.020 |
Why?
| Virus Replication | 1 | 2011 | 395 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1140 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2012 | 1230 | 0.020 |
Why?
| Quality of Life | 1 | 2019 | 2353 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 4694 | 0.020 |
Why?
| Cranial Irradiation | 1 | 2008 | 66 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 338 | 0.020 |
Why?
| Radiotherapy, Adjuvant | 1 | 2008 | 182 | 0.020 |
Why?
| Umbilical Veins | 1 | 2007 | 58 | 0.020 |
Why?
| Granzymes | 1 | 2007 | 40 | 0.020 |
Why?
| Apolipoprotein C-I | 1 | 2006 | 1 | 0.020 |
Why?
| Complement C1 Inactivator Proteins | 1 | 2006 | 6 | 0.020 |
Why?
| Apolipoproteins C | 1 | 2006 | 6 | 0.020 |
Why?
| Serum Amyloid A Protein | 1 | 2006 | 29 | 0.020 |
Why?
| Prealbumin | 1 | 2006 | 22 | 0.020 |
Why?
| Minnesota | 1 | 2007 | 134 | 0.020 |
Why?
| Maternal Age | 1 | 2006 | 117 | 0.020 |
Why?
| Blood Transfusion | 1 | 2008 | 293 | 0.020 |
Why?
| DNA Primers | 1 | 2007 | 510 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 60 | 0.020 |
Why?
| Endotoxins | 1 | 2006 | 211 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2005 | 113 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2009 | 506 | 0.020 |
Why?
| Kidney Neoplasms | 1 | 2009 | 327 | 0.020 |
Why?
| Disease Progression | 1 | 2011 | 2380 | 0.010 |
Why?
| Reference Values | 1 | 2006 | 743 | 0.010 |
Why?
| Glycoproteins | 1 | 2006 | 304 | 0.010 |
Why?
| Universities | 1 | 2007 | 340 | 0.010 |
Why?
| Lung Transplantation | 1 | 2006 | 246 | 0.010 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2006 | 590 | 0.010 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2005 | 470 | 0.010 |
Why?
| Odds Ratio | 1 | 2006 | 953 | 0.010 |
Why?
| Cell Membrane | 1 | 2007 | 680 | 0.010 |
Why?
| Annexin A5 | 1 | 2003 | 22 | 0.010 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 367 | 0.010 |
Why?
| Caspase 8 | 1 | 2003 | 43 | 0.010 |
Why?
| Erythropoiesis | 1 | 2003 | 33 | 0.010 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2003 | 22 | 0.010 |
Why?
| Membrane Potentials | 1 | 2003 | 248 | 0.010 |
Why?
| Cytoskeletal Proteins | 1 | 2003 | 145 | 0.010 |
Why?
| Proteome | 1 | 2005 | 339 | 0.010 |
Why?
| Leukemia, B-Cell | 1 | 2002 | 11 | 0.010 |
Why?
| Hemolysis | 1 | 2003 | 146 | 0.010 |
Why?
| Caspases | 1 | 2003 | 245 | 0.010 |
Why?
| Luciferases | 1 | 2002 | 142 | 0.010 |
Why?
| Creatine | 1 | 2001 | 50 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2009 | 1013 | 0.010 |
Why?
| Tissue Distribution | 1 | 2001 | 286 | 0.010 |
Why?
| Immunoblotting | 1 | 2001 | 283 | 0.010 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2001 | 42 | 0.010 |
Why?
| RNA | 1 | 2007 | 809 | 0.010 |
Why?
| Diabetes Mellitus | 1 | 2009 | 900 | 0.010 |
Why?
| Blood Proteins | 1 | 2003 | 231 | 0.010 |
Why?
| Luminescent Proteins | 1 | 2002 | 166 | 0.010 |
Why?
| Neoplasm Transplantation | 1 | 2001 | 228 | 0.010 |
Why?
| Hydrogen-Ion Concentration | 1 | 2001 | 511 | 0.010 |
Why?
| Green Fluorescent Proteins | 1 | 2002 | 371 | 0.010 |
Why?
| Cell Death | 1 | 2001 | 323 | 0.010 |
Why?
| Thymus Gland | 1 | 2001 | 296 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2001 | 849 | 0.010 |
Why?
| Cell Division | 1 | 2001 | 758 | 0.010 |
Why?
| Transfection | 1 | 2002 | 866 | 0.010 |
Why?
| Spleen | 1 | 2001 | 487 | 0.010 |
Why?
| Phosphorylation | 1 | 2001 | 1569 | 0.010 |
Why?
| Gene Expression | 1 | 2001 | 1421 | 0.010 |
Why?
|
|
Verneris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|